We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 11,807

FDA Update: Adulterated and Illegal - FDA's New Guidance on Highly Concentrated Caffeine Dietary Supplement Products
  • Porzio Bromberg & Newman PC
  • USA
  • April 25 2018

On April 13, 2018, the Food and Drug Administration (FDA or Agency) issued a guidance for industry entitled "Highly Concentrated Caffeine in Dietary


FDA Advisory Committee Issues First Ever Approval for Plant-Based Pharmaceutical Cannabidiol Product to Treat Seizures in Patients with Severe Forms of Epilepsy
  • GrayRobinson PA
  • USA
  • April 25 2018

GW Pharmaceuticals plc (Nasdaq:GWPH), a biopharmaceutical company focused on commercializing novel therapeutics from its proprietary cannabinoid


FDA Issues Two Guidances on Next Generation Sequencing
  • Reed Smith LLP
  • USA
  • April 24 2018

This guest post is from Reed Smith‘s Matt Jacobson, who is keeping us up to date with the FDA’s initiatives concerning pharmacogenomics and


Food Labeling Update
  • McGuireWoods LLP
  • USA
  • April 24 2018

One ongoing dispute in the world of food labeling has been the U.S. Food & Drug Administration's efforts to define the term "natural." After years of


US FDA Approaches to Artificial Intelligence
  • Drinker Biddle & Reath LLP
  • USA
  • April 24 2018

Artificial Intelligence (AI) can be employed in a health care setting for a variety of tasks, from managing electronic health records at a hospital


Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • April 23 2018

Health & Human Services (HHS) Secretary Alex Azar is recovering at his home in Indianapolis following his second hospitalization in less than a week


Washington Healthcare Update - Apr 23, 2018
  • McGuireWoods LLP
  • USA
  • April 23 2018

The House Energy & Commerce Health Subcommittee will mark up opioid legislation on April 25. The markup is scheduled for the day after the Senate


FDA Draft Guidance on Metered Dose Inhaler and Dry Powder Inhaler Products
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • April 23 2018

On April 18, 2018, FDA issued draft guidance on Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) ProductsQuality Considerations. The guidance


FDA finalizes guidances for NGS-based tests
  • Hogan Lovells
  • USA
  • April 20 2018

On April 12, 2018, the U.S. Food and Drug Administration (FDA or the Agency) finalized two guidances on the oversight of next generation sequencing


Unanimous Recommendation for Cannabis-Based Epilepsy Drug; Trump Administration Lifts Threat of Cannabis Enforcement in States With Legalization; Schumer To Introduce Bill Decriminalizing Marijuana
  • Kelley Drye & Warren LLP
  • USA
  • April 20 2018

On this auspicious April 20th, three developments in the world of cannabis regulation caught our attention. The first is the unanimous recommendation